Goldman Sachs Maintains Neutral on MorphoSys, Lowers Price Target to $4.75
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Rajan Sharma has maintained a Neutral rating on MorphoSys (NASDAQ:MOR) but has reduced the price target from $9.25 to $4.75.

November 22, 2023 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has lowered the price target for MorphoSys from $9.25 to $4.75, maintaining a Neutral rating.
A reduction in the price target by a major analyst like Goldman Sachs can be seen as a negative signal, potentially leading to a decrease in investor confidence and a short-term drop in the stock price. The maintenance of a Neutral rating suggests that the analyst sees limited upside or downside potential, but the significant cut in the price target is likely to be the dominant factor in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100